KR20220102669A - 인간 인테그린 α4β7의 억제 - Google Patents

인간 인테그린 α4β7의 억제 Download PDF

Info

Publication number
KR20220102669A
KR20220102669A KR1020227015040A KR20227015040A KR20220102669A KR 20220102669 A KR20220102669 A KR 20220102669A KR 1020227015040 A KR1020227015040 A KR 1020227015040A KR 20227015040 A KR20227015040 A KR 20227015040A KR 20220102669 A KR20220102669 A KR 20220102669A
Authority
KR
South Korea
Prior art keywords
compound
substituted
unsubstituted
certain embodiments
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227015040A
Other languages
English (en)
Korean (ko)
Inventor
매튜 쥐. 부르사비치
단 쿠이
제임스 이. 다울링
크리스토퍼 엔. 한
브라이스 에이. 해리슨
푸-양 린
블레이즈 에스. 리파
브루스 엔. 로저스
돈 엠. 트로스트
쳉 종
카일 디. 콘제
알렉세이 아이. 게라슈토
병찬 김
살마 라피
타일러 데이
유진 히키
에블린 황
로버트 잘러
Original Assignee
모픽 테라퓨틱, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 모픽 테라퓨틱, 인코포레이티드 filed Critical 모픽 테라퓨틱, 인코포레이티드
Publication of KR20220102669A publication Critical patent/KR20220102669A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Indole Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Radio Relay Systems (AREA)
  • Air Conditioning Control Device (AREA)
KR1020227015040A 2019-10-16 2020-10-16 인간 인테그린 α4β7의 억제 Ceased KR20220102669A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962916062P 2019-10-16 2019-10-16
US62/916,062 2019-10-16
PCT/US2020/055986 WO2021076890A1 (en) 2019-10-16 2020-10-16 INHIBITING HUMAN INTEGRIN α4β7

Publications (1)

Publication Number Publication Date
KR20220102669A true KR20220102669A (ko) 2022-07-20

Family

ID=73198501

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020227015040A Ceased KR20220102669A (ko) 2019-10-16 2020-10-16 인간 인테그린 α4β7의 억제
KR1020237015039A Pending KR20230088376A (ko) 2019-10-16 2021-10-15 인간 인테그린 a4b7 억제

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020237015039A Pending KR20230088376A (ko) 2019-10-16 2021-10-15 인간 인테그린 a4b7 억제

Country Status (37)

Country Link
US (3) US20240174632A1 (cg-RX-API-DMAC7.html)
EP (3) EP4045039B1 (cg-RX-API-DMAC7.html)
JP (7) JP7437490B2 (cg-RX-API-DMAC7.html)
KR (2) KR20220102669A (cg-RX-API-DMAC7.html)
CN (4) CN119192137A (cg-RX-API-DMAC7.html)
AR (1) AR120244A1 (cg-RX-API-DMAC7.html)
AU (3) AU2020366435B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022007284A2 (cg-RX-API-DMAC7.html)
CA (1) CA3154269A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022000959A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022005759A2 (cg-RX-API-DMAC7.html)
CR (1) CR20220205A (cg-RX-API-DMAC7.html)
CU (1) CU20220027A7 (cg-RX-API-DMAC7.html)
DK (1) DK4045039T3 (cg-RX-API-DMAC7.html)
DO (2) DOP2022000081A (cg-RX-API-DMAC7.html)
EC (1) ECSP22038978A (cg-RX-API-DMAC7.html)
ES (1) ES3035561T3 (cg-RX-API-DMAC7.html)
FI (1) FI4045039T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20250749T1 (cg-RX-API-DMAC7.html)
HU (1) HUE071814T2 (cg-RX-API-DMAC7.html)
IL (2) IL319053A (cg-RX-API-DMAC7.html)
LT (1) LT4045039T (cg-RX-API-DMAC7.html)
MA (1) MA57399B1 (cg-RX-API-DMAC7.html)
MD (1) MD4045039T2 (cg-RX-API-DMAC7.html)
MX (1) MX2022004406A (cg-RX-API-DMAC7.html)
PE (1) PE20221829A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022550886A1 (cg-RX-API-DMAC7.html)
PL (1) PL4045039T3 (cg-RX-API-DMAC7.html)
PT (1) PT4045039T (cg-RX-API-DMAC7.html)
PY (1) PY2065718A (cg-RX-API-DMAC7.html)
RS (1) RS66976B1 (cg-RX-API-DMAC7.html)
SI (1) SI4045039T1 (cg-RX-API-DMAC7.html)
TW (7) TWI775182B (cg-RX-API-DMAC7.html)
UA (1) UA130059C2 (cg-RX-API-DMAC7.html)
UY (1) UY38926A (cg-RX-API-DMAC7.html)
WO (3) WO2021076890A1 (cg-RX-API-DMAC7.html)
ZA (2) ZA202203872B (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202528300A (zh) 2018-04-12 2025-07-16 美商莫菲克醫療股份有限公司 人類整合素α4β7拮抗劑
DK3873884T3 (da) 2018-10-30 2025-02-17 Gilead Sciences Inc 3-(quinolin-8-yl)-1,4-dihydropyrido[3,4-d]pyrimidin-2,4-dion-derivater som alpha4beta7-integrinhæmmere til behandling af inflammatoriske sygdomme
BR112021022659A2 (pt) 2019-05-15 2022-03-29 Chemocentryx Inc Compostos triarílicos para o tratamento de doenças pd-l1
AU2020329207B2 (en) 2019-08-14 2024-02-29 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
BR112022007284A2 (pt) * 2019-10-16 2022-07-05 Morphic Therapeutic Inc Inibição de integrina humana alpha-4 beta-7
AU2020368392B2 (en) 2019-10-16 2026-01-08 Chemocentryx, Inc. Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases
ES3068390T3 (en) 2019-10-16 2026-05-29 Chemocentryx Inc Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases
US20250195485A1 (en) * 2021-12-27 2025-06-19 Xizang Haisco Pharmaceutical Co., Ltd. Propionic acid derivative and medical use thereof
EP4585587A1 (en) 2022-09-09 2025-07-16 Xizang Haisco Pharmaceutical Co., Ltd. Propionic acid derivative and use thereof in medicine
CN120500479A (zh) 2022-12-22 2025-08-15 新特拉有限公司 α4β7整联蛋白拮抗剂及其用途
CN120957974A (zh) * 2023-02-21 2025-11-14 希四克斯探索有限公司 大环α4β7整合素抑制剂
WO2024249328A2 (en) 2023-05-26 2024-12-05 Adarx Pharmaceuticals, Inc. Sod1-modulating compositions and methods of use thereof
WO2025026955A1 (en) * 2023-07-28 2025-02-06 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
AU2024317579A1 (en) 2023-07-28 2026-02-05 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Benzo nitrogen-containing heterocyclic derivative regulator, preparation method therefor and use thereof
WO2025176107A1 (zh) * 2024-02-20 2025-08-28 西藏海思科制药有限公司 一种吡啶酮衍生物及其在医药上的应用
CN118702712B (zh) * 2024-07-04 2025-11-11 安徽普利药业有限公司 一种n-(3-苯10硼酸)-l-天冬氨酸中间体制备方法
WO2026018016A1 (en) * 2024-07-19 2026-01-22 C4X Discovery Limited Therapeutic compounds
WO2026018017A1 (en) * 2024-07-19 2026-01-22 C4X Discovery Limited Therapeutic compounds
CN119504796B (zh) * 2024-11-20 2026-03-10 南通大学附属医院 一种具有抗肿瘤活性的化合物及其应用
WO2026138844A1 (zh) * 2024-12-24 2026-07-02 湖北生物医药产业技术研究院有限公司 酰胺类化合物及其作为整合素α4β7拮抗剂的用途
WO2026156089A1 (en) 2025-01-17 2026-07-23 Eli Lilly And Company Small molecule alpha4beta7 integrin inhibitor for use in the treatment of inflammatory bowel disease

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69425431T2 (de) 1993-03-31 2001-02-08 G.D. Searle & Co., Chicago 1-amdinophenyl-pyrrolidone/piperidinone als blutblättchen-aggregations inhibitoren
DE4427979A1 (de) 1993-11-15 1996-02-15 Cassella Ag Substituierte 5-Ring-Heterocyclen, ihre Herstellung und ihre Verwendung
US5849736A (en) 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
DE19622489A1 (de) 1996-06-05 1997-12-11 Hoechst Ag Salze des 3-(2-(4-(4-(Amino-imino-methyl)-phenyl)-4- methyl-2,5-dioxo-imidazolidin-1-yl)-acetylamino)-3- phenyl-propionsäure-ethylesters
CA2268381A1 (en) 1996-10-11 1998-04-23 Cor Therapeutics, Inc. Selective factor xa inhibitors
WO1998016524A1 (en) 1996-10-11 1998-04-23 Cor Therapeutics, Inc. HETEROCYCLIC DERIVATIVES AS FACTOR Xa INHIBITORS
DE19751251A1 (de) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
US6645939B1 (en) 1997-11-24 2003-11-11 Merck & Co., Inc. Substituted β-alanine derivatives as cell adhesion inhibitors
ES2221227T3 (es) 1997-11-24 2004-12-16 MERCK & CO., INC. Derivados sustituidos de beta-alanina como inhibidores de la adhesion celular.
MY153569A (en) 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
WO2000000481A1 (en) 1998-06-29 2000-01-06 Du Pont Pharmaceuticals Company Cyclic carbamates and isoxazolidines as iib/iiia antagonists
WO2000006169A1 (en) * 1998-07-29 2000-02-10 Merck & Co., Inc. Integrin receptor antagonists
GB9826174D0 (en) * 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
US6723711B2 (en) * 1999-05-07 2004-04-20 Texas Biotechnology Corporation Propanoic acid derivatives that inhibit the binding of integrins to their receptors
SK288186B6 (sk) * 1999-05-07 2014-05-06 Encysive Pharmaceuticals, Inc. Deriváty kyseliny propiónovej, ktoré inhibujú väzbu integrínov na ich receptory, farmaceutické kompozície s ich obsahom a ich použitie
US6972296B2 (en) 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
EP1214292B1 (en) 1999-09-24 2007-06-13 Genentech, Inc. Tyrosine derivatives
DE10041423A1 (de) 2000-08-23 2002-03-07 Merck Patent Gmbh Biphenylderivate
BR0113671A (pt) * 2000-08-30 2004-01-06 Pharmacia Corp Antagonistas de integrina alfa v beta 3 gem-substituìda
DE10111876A1 (de) 2001-03-10 2002-09-19 Aventis Pharma Gmbh Bis(trifluormethyl)hydantoine als Zwischenprodukte für pharmazeutische Wirkstoffe
DE10154280A1 (de) 2001-11-05 2003-05-15 Wilex Ag Antagonisten für alpha¶4¶-Integrine
KR20040105740A (ko) 2002-02-25 2004-12-16 엘란 파마슈티칼스, 인크. 염증 치료제의 투여 방법
ES2377979T3 (es) 2004-09-03 2012-04-03 Genentech, Inc. Antagonistas anti-beta7 humanizados y utilizaciones para los mismos
ES2387317T3 (es) 2005-03-03 2012-09-20 Seedlings Life Science Ventures, Llc. Procedimiento de control de riesgos de pacientes en tratamiento con natalizumab
WO2006126529A1 (ja) 2005-05-25 2006-11-30 Shionogi & Co., Ltd. 6,7-不飽和-7-カルバモイル置換モルヒナン誘導体
CA2610800A1 (en) 2005-06-09 2006-12-14 Ucb Pharma, S.A. 2,6 quinolinyl derivatives, processes for preparing them and their use as medicament
HUE047230T2 (hu) 2006-02-28 2020-04-28 Biogen Ma Inc Gyulladásos és autoimmun betegségek natalizumabbal való kezelésének módszerei
US20100272680A1 (en) 2009-02-09 2010-10-28 Subramanian Baskaran Piperidinyl Cyclic Amido Antiviral Agents
MX2013011130A (es) 2011-03-31 2013-10-30 Genentech Inc Metodos de administracion de antagonistas de integrina beta7.
KR101850591B1 (ko) 2012-10-05 2018-04-19 제넨테크, 인크. 염증성 장 질환의 진단 및 치료 방법
JP7054990B2 (ja) 2014-03-27 2022-04-15 ジェネンテック, インコーポレイテッド 炎症性腸疾患の診断及び治療のための方法
CN105658641B (zh) 2014-07-25 2018-04-17 江苏恒瑞医药股份有限公司 氮茚‑酰胺类衍生物、其制备方法及其在医药上的应用
EP3224280A1 (en) * 2014-11-26 2017-10-04 Millennium Pharmaceuticals, Inc. Vedolizumab for the treatment of fistulizing crohn's disease
EP3978530A1 (en) 2015-02-26 2022-04-06 F. Hoffmann-La Roche AG Integrin beta7 antagonists and methods of treating crohn's disease
EP4159727B1 (en) * 2017-02-28 2026-04-08 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
US10875875B2 (en) * 2017-04-26 2020-12-29 Aviara Pharmaceuticals, Inc. Propionic acid derivatives and methods of use thereof
US10246451B2 (en) 2017-04-26 2019-04-02 Aviara Pharmaceuticals, Inc. Propionic acid derivatives and methods of use thereof
TW202528300A (zh) * 2018-04-12 2025-07-16 美商莫菲克醫療股份有限公司 人類整合素α4β7拮抗劑
DK3873884T3 (da) 2018-10-30 2025-02-17 Gilead Sciences Inc 3-(quinolin-8-yl)-1,4-dihydropyrido[3,4-d]pyrimidin-2,4-dion-derivater som alpha4beta7-integrinhæmmere til behandling af inflammatoriske sygdomme
WO2020092394A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
WO2020092401A1 (en) * 2018-10-30 2020-05-07 Gilead Sciences, Inc. COMPOUNDS FOR INHIBITION OF ALPHA 4β7 INTEGRIN
ES2987796T3 (es) * 2018-10-30 2024-11-18 Gilead Sciences Inc Derivados de N-benzoil-fenilalanina como inhibidores de la integrina alfa4beta7 para el tratamiento de enfermedades inflamatorias
BR112022007284A2 (pt) * 2019-10-16 2022-07-05 Morphic Therapeutic Inc Inibição de integrina humana alpha-4 beta-7

Also Published As

Publication number Publication date
AU2021361031A1 (en) 2023-06-08
JP2024054296A (ja) 2024-04-16
AU2026206251A1 (en) 2026-08-06
JP7209116B2 (ja) 2023-01-19
ZA202203872B (en) 2024-01-31
CR20220205A (es) 2022-07-22
SI4045039T1 (sl) 2025-07-31
US11104661B1 (en) 2021-08-31
JP2023036958A (ja) 2023-03-14
TWI775182B (zh) 2022-08-21
ES3035561T3 (en) 2025-09-04
RS66976B1 (sr) 2025-07-31
MD4045039T2 (ro) 2025-11-30
JP7437490B2 (ja) 2024-02-22
EP4045039B1 (en) 2025-04-23
JP2024054293A (ja) 2024-04-16
EP4228634A1 (en) 2023-08-23
TWI791304B (zh) 2023-02-01
TW202126624A (zh) 2021-07-16
IL319053A (en) 2025-04-01
CN119192137A (zh) 2024-12-27
CU20220027A7 (es) 2022-12-12
WO2021076902A1 (en) 2021-04-22
UY38926A (es) 2021-05-31
TW202500559A (zh) 2025-01-01
AU2020366435A1 (en) 2022-04-21
TW202222793A (zh) 2022-06-16
TWI857592B (zh) 2024-10-01
LT4045039T (lt) 2025-08-11
EP4559525A3 (en) 2025-08-20
WO2021076890A1 (en) 2021-04-22
DOP2025000034A (es) 2025-04-08
ECSP22038978A (es) 2022-06-30
PY2065718A (es) 2023-01-17
CO2022005759A2 (es) 2022-05-20
TW202315868A (zh) 2023-04-16
CN116783161A (zh) 2023-09-19
EP4045039A4 (en) 2023-12-13
TW202500558A (zh) 2025-01-01
FI4045039T3 (fi) 2025-06-20
JP7437495B2 (ja) 2024-02-22
IL292296A (en) 2022-06-01
JP2024116230A (ja) 2024-08-27
CL2022000959A1 (es) 2023-04-28
IL292296B2 (en) 2025-07-01
TWI900200B (zh) 2025-10-01
PL4045039T3 (pl) 2025-09-15
JP7702004B2 (ja) 2025-07-02
CA3154269A1 (en) 2021-04-22
PH12022550886A1 (en) 2023-05-03
TW202244040A (zh) 2022-11-16
TWI888065B (zh) 2025-06-21
TW202332675A (zh) 2023-08-16
DOP2022000081A (es) 2022-07-31
UA130059C2 (uk) 2025-10-29
JP7717202B2 (ja) 2025-08-01
HUE071814T2 (hu) 2025-09-28
KR20230088376A (ko) 2023-06-19
CN115087444A (zh) 2022-09-20
AU2020366435B2 (en) 2026-05-28
TWI840047B (zh) 2024-04-21
WO2022081983A1 (en) 2022-04-21
CN115087444B (zh) 2024-09-17
JP7869261B2 (ja) 2026-06-02
US11370773B1 (en) 2022-06-28
CN116783161B (zh) 2026-04-03
IL292296B1 (en) 2025-03-01
JP2022542184A (ja) 2022-09-29
DK4045039T3 (da) 2025-06-30
TWI802477B (zh) 2023-05-11
WO2021076890A4 (en) 2021-06-10
MA57399B1 (fr) 2025-06-30
PE20221829A1 (es) 2022-11-29
JP2023500437A (ja) 2023-01-06
US20240174632A1 (en) 2024-05-30
ZA202303992B (en) 2024-06-26
CN122251398A (zh) 2026-06-23
HRP20250749T1 (hr) 2025-08-15
JP7500785B2 (ja) 2024-06-17
JP2022548809A (ja) 2022-11-22
BR112022007284A2 (pt) 2022-07-05
AR120244A1 (es) 2022-02-09
MX2022004406A (es) 2022-08-25
EP4045039A1 (en) 2022-08-24
EP4228634A4 (en) 2024-12-18
PT4045039T (pt) 2025-07-02
EP4559525B1 (en) 2026-08-05
EP4559525A2 (en) 2025-05-28

Similar Documents

Publication Publication Date Title
TWI900200B (zh) 抑制人類整合素αβ
EA052724B1 (ru) ИНГИБИРОВАНИЕ ИНТЕГРИНА ЧЕЛОВЕКА α4β7
OA21139A (en) Inhibiting human integrin ALPHA4BETA7.
WO2022247796A1 (zh) 周期蛋白依赖性激酶9抑制剂的用途

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601